Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.

Wall Street's major indexes faced declines as President Trump's announcement of upcoming pharmaceutical tariffs rekindled ...